Daiichi Sankyo settles its cardio drug lawsuit with Esperion, which will get $125M milestone payment
03 Jan 2024
Patent InfringementAHA
Daiichi Sankyo Europe and Esperion Therapeutics have agreed to a $125 million change to their collaboration agreement, settling a legal dispute that erupted after the trial readout of the cardiovascular drug on which they are partnered.
The companies announced Wednesday that Daiichi Sankyo would pay Esperion $100 million this month ahead of potential approvals by the European Medicines Agency for two cardiovascular drugs: Nilemdo and Nustendi (marketed in the US as Nexletol and Nexlizet, respectively). Daiichi will also pay an additional $25 million to Esperion in the quarter after the EMA’s decision on the pending application for the drugs.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.